Discovery Pharmacology Overview

Note: Effective October 1, 2012, the Discovery Pharmacology business has been acquired by Eurofins and will be called Eurofins-Panlabs.  Although the name has changed, the facilities, employees, and capabilities are the same!  Please contact Client Services at 1 800 726 5229, ext. 8217 with any questions or concerns.

Comprehensive Portfolio Reduces Risk, Lowers Cost and Speeds Discovery

With the broadest portfolio in the industry of more than 1,300 in vitro and in vivo assays, Ricerca’s discovery pharmacology capabilities help you quickly detect compounds likely to fail in the clinic and select candidates with the highest potential for success. From our modern facilities in Bothell, Washington, and Taipei, Taiwan, we provide a full range of discovery pharmacology services, including:

• Radioligand receptor binding

• Radiometric enzyme

• Cellular/functional assays

• In vitro toxicity

• OncoPanel anti-cancer screening

• ImmunoSignal biomarker services

• In vivo disease models

• In vivo safety screening models

• Foresight on-demand predictive data analysis services